
2001-08-08
Small
0personInquired
0personFavorited
ConnectType:
T - Technology & Patents
Industry:
Pharmaceuticals and Chemical IntermediatesFine Chemical ManufacturingChemical Engineering Technology Research and Development and Process Package
Country / Region:
China
Company Type:
Listed company
Registered Capital:
378 million RMB
Company Capability: Chemical Technology & Patents、Process Technology Development、Process Package Design
Sanmenxia Sinovia Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, with long-standing expertise in the macrolide antibiotic field. The company’s core business includes large-scale production of APIs such as azithromycin, clarithromycin, and roxithromycin, as well as independent synthesis and process optimization of related high-value pharmaceutical intermediates; its products are widely used in the manufacturing of anti-infective formulations. Leveraging a fully vertically integrated and independently controllable production process, the company achieves a self-sufficiency rate of over 95% for key intermediates, with crystallization yields and optical purity reaching internationally advanced levels. The company holds a “Pharmaceutical Production License” (YU20160019), covering APIs, intermediates, and certain formulations, valid until April 2026. Its azithromycin API has obtained the European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of a Suitability of a Monograph to the European Pharmacopoeia (CEP) (CEP 2022-375, valid until 2027) and successfully passed an on-site inspection by the U.S. Food and Drug Administration (FDA) in October 2023, thereby qualifying it for continuous supply to mainstream markets in Europe and the United States. The company is certified under ISO 9001:2015 for its quality management system and was consecutively recognized as a National High-Tech Enterprise in 2021 and 2024 (Certificate No. GR202141000287; Record No. GR202441000312). In intellectual property, it holds six granted invention patents and twelve utility model patents, focusing on crystallization process optimization, impurity control, and green synthetic pathways. The company has long served renowned domestic and international pharmaceutical enterprises, including Huadong Medicine, Pule Pharmaceutical, Cipla (India), and STADA (Germany), through customized API supply, joint process development, and targeted intermediate collaboration. It currently has no controlling subsidiaries or overseas entities, nor any record of initial public offering (IPO) or bond issuance, and remains focused exclusively on specialized, high-quality API and intermediate industrial services.
Connect
More Suppliers科林能源技术(北京)有限公司
77
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp
凯铭科技(杭州)有限公司
79
0
T - Technology & Patents
P - Procurement
Dalian Pace Gas Equipment Co., Ltd.
112
0
T - Technology & Patents
E - Engineering Design
P - Procurement
S - Site & Revamp





































